カテゴリー： Market Monitor Global, 世界, 医療/バイオ

抗肥満薬の世界市場見通し2023年-2029年

◆英語タイトル：Anti-obesity Medicine Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5688）◆商品コード：MMG23JU5688
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月
◆ページ数：60
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Anti-obesity Medicine Market 調査レポートは次の情報を含め、グローバルにおけるの抗肥満薬市場規模と予測を収録しています。・世界の抗肥満薬市場：売上、2018年-2023年、2024年-2029年
・世界の抗肥満薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の抗肥満薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「医療用医薬品」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

抗肥満薬のグローバル主要企業は、Alizyme、 Amylin Pharmaceuticals、 Arena Pharmaceuticals、 Boehringer Ingelheim、 Eisai、 GlaxoSmithKline、 Orexigen Therapeutics、 Vivus、 Pfizer、 Roche、 Merck、 Novo Nordiskなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、抗肥満薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の抗肥満薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の抗肥満薬市場：タイプ別市場シェア、2022年
・医療用医薬品、OTC医薬品

世界の抗肥満薬市場：用途別、2018年-2023年、2024年-2029年
世界の抗肥満薬市場：用途別市場シェア、2022年
・男性、女性

世界の抗肥満薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の抗肥満薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における抗肥満薬のグローバル売上、2018年-2023年
・主要企業における抗肥満薬のグローバル売上シェア、2022年
・主要企業における抗肥満薬のグローバル販売量、2018年-2023年
・主要企業における抗肥満薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Alizyme、 Amylin Pharmaceuticals、 Arena Pharmaceuticals、 Boehringer Ingelheim、 Eisai、 GlaxoSmithKline、 Orexigen Therapeutics、 Vivus、 Pfizer、 Roche、 Merck、 Novo Nordisk

*************************************************************

・調査・分析レポートの概要
抗肥満薬市場の定義
市場セグメント
世界の抗肥満薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の抗肥満薬市場規模
世界の抗肥満薬市場規模：2022年 VS 2029年
世界の抗肥満薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの抗肥満薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の抗肥満薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：医療用医薬品、OTC医薬品
抗肥満薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：男性、女性
抗肥満薬の用途別グローバル売上・予測

・地域別市場分析
地域別抗肥満薬市場規模 2022年と2029年
地域別抗肥満薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Alizyme、 Amylin Pharmaceuticals、 Arena Pharmaceuticals、 Boehringer Ingelheim、 Eisai、 GlaxoSmithKline、 Orexigen Therapeutics、 Vivus、 Pfizer、 Roche、 Merck、 Novo Nordisk
...

Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control weight.
This report aims to provide a comprehensive presentation of the global market for Anti-obesity Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-obesity Medicine. This report contains market size and forecasts of Anti-obesity Medicine in global, including the following market information:
Global Anti-obesity Medicine Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Anti-obesity Medicine market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Prescription Drugs Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Anti-obesity Medicine include Alizyme, Amylin Pharmaceuticals, Arena Pharmaceuticals, Boehringer Ingelheim, Eisai, GlaxoSmithKline, Orexigen Therapeutics, Vivus and Pfizer, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Anti-obesity Medicine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Anti-obesity Medicine Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Anti-obesity Medicine Market Segment Percentages, by Type, 2022 (%)
Prescription Drugs
OTC Drugs
Global Anti-obesity Medicine Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Anti-obesity Medicine Market Segment Percentages, by Application, 2022 (%)
Men
Women
Global Anti-obesity Medicine Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Anti-obesity Medicine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Anti-obesity Medicine revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Anti-obesity Medicine revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Alizyme
Amylin Pharmaceuticals
Arena Pharmaceuticals
Boehringer Ingelheim
Eisai
GlaxoSmithKline
Orexigen Therapeutics
Vivus
Pfizer
Roche
Merck
Novo Nordisk
Outline of Major Chapters:
Chapter 1: Introduces the definition of Anti-obesity Medicine, market overview.
Chapter 2: Global Anti-obesity Medicine market size in revenue.
Chapter 3: Detailed analysis of Anti-obesity Medicine company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-obesity Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Anti-obesity Medicine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Anti-obesity Medicine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Anti-obesity Medicine Overall Market Size
2.1 Global Anti-obesity Medicine Market Size: 2022 VS 2029
2.2 Global Anti-obesity Medicine Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Anti-obesity Medicine Players in Global Market
3.2 Top Global Anti-obesity Medicine Companies Ranked by Revenue
3.3 Global Anti-obesity Medicine Revenue by Companies
3.4 Top 3 and Top 5 Anti-obesity Medicine Companies in Global Market, by Revenue in 2022
3.5 Global Companies Anti-obesity Medicine Product Type
3.6 Tier 1, Tier 2 and Tier 3 Anti-obesity Medicine Players in Global Market
3.6.1 List of Global Tier 1 Anti-obesity Medicine Companies
3.6.2 List of Global Tier 2 and Tier 3 Anti-obesity Medicine Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Anti-obesity Medicine Market Size Markets, 2022 & 2029
4.1.2 Prescription Drugs
4.1.3 OTC Drugs
4.2 By Type – Global Anti-obesity Medicine Revenue & Forecasts
4.2.1 By Type – Global Anti-obesity Medicine Revenue, 2018-2023
4.2.2 By Type – Global Anti-obesity Medicine Revenue, 2024-2029
4.2.3 By Type – Global Anti-obesity Medicine Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Anti-obesity Medicine Market Size, 2022 & 2029
5.1.2 Men
5.1.3 Women
5.2 By Application – Global Anti-obesity Medicine Revenue & Forecasts
5.2.1 By Application – Global Anti-obesity Medicine Revenue, 2018-2023
5.2.2 By Application – Global Anti-obesity Medicine Revenue, 2024-2029
5.2.3 By Application – Global Anti-obesity Medicine Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Anti-obesity Medicine Market Size, 2022 & 2029
6.2 By Region – Global Anti-obesity Medicine Revenue & Forecasts
6.2.1 By Region – Global Anti-obesity Medicine Revenue, 2018-2023
6.2.2 By Region – Global Anti-obesity Medicine Revenue, 2024-2029
6.2.3 By Region – Global Anti-obesity Medicine Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Anti-obesity Medicine Revenue, 2018-2029
6.3.2 US Anti-obesity Medicine Market Size, 2018-2029
6.3.3 Canada Anti-obesity Medicine Market Size, 2018-2029
6.3.4 Mexico Anti-obesity Medicine Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Anti-obesity Medicine Revenue, 2018-2029
6.4.2 Germany Anti-obesity Medicine Market Size, 2018-2029
6.4.3 France Anti-obesity Medicine Market Size, 2018-2029
6.4.4 U.K. Anti-obesity Medicine Market Size, 2018-2029
6.4.5 Italy Anti-obesity Medicine Market Size, 2018-2029
6.4.6 Russia Anti-obesity Medicine Market Size, 2018-2029
6.4.7 Nordic Countries Anti-obesity Medicine Market Size, 2018-2029
6.4.8 Benelux Anti-obesity Medicine Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Anti-obesity Medicine Revenue, 2018-2029
6.5.2 China Anti-obesity Medicine Market Size, 2018-2029
6.5.3 Japan Anti-obesity Medicine Market Size, 2018-2029
6.5.4 South Korea Anti-obesity Medicine Market Size, 2018-2029
6.5.5 Southeast Asia Anti-obesity Medicine Market Size, 2018-2029
6.5.6 India Anti-obesity Medicine Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Anti-obesity Medicine Revenue, 2018-2029
6.6.2 Brazil Anti-obesity Medicine Market Size, 2018-2029
6.6.3 Argentina Anti-obesity Medicine Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Anti-obesity Medicine Revenue, 2018-2029
6.7.2 Turkey Anti-obesity Medicine Market Size, 2018-2029
6.7.3 Israel Anti-obesity Medicine Market Size, 2018-2029
6.7.4 Saudi Arabia Anti-obesity Medicine Market Size, 2018-2029
6.7.5 UAE Anti-obesity Medicine Market Size, 2018-2029
7 Anti-obesity Medicine Companies Profiles
7.1 Alizyme
7.1.1 Alizyme Company Summary
7.1.2 Alizyme Business Overview
7.1.3 Alizyme Anti-obesity Medicine Major Product Offerings
7.1.4 Alizyme Anti-obesity Medicine Revenue in Global Market (2018-2023)
7.1.5 Alizyme Key News & Latest Developments
7.2 Amylin Pharmaceuticals
7.2.1 Amylin Pharmaceuticals Company Summary
7.2.2 Amylin Pharmaceuticals Business Overview
7.2.3 Amylin Pharmaceuticals Anti-obesity Medicine Major Product Offerings
7.2.4 Amylin Pharmaceuticals Anti-obesity Medicine Revenue in Global Market (2018-2023)
7.2.5 Amylin Pharmaceuticals Key News & Latest Developments
7.3 Arena Pharmaceuticals
7.3.1 Arena Pharmaceuticals Company Summary
7.3.2 Arena Pharmaceuticals Business Overview
7.3.3 Arena Pharmaceuticals Anti-obesity Medicine Major Product Offerings
7.3.4 Arena Pharmaceuticals Anti-obesity Medicine Revenue in Global Market (2018-2023)
7.3.5 Arena Pharmaceuticals Key News & Latest Developments
7.4 Boehringer Ingelheim
7.4.1 Boehringer Ingelheim Company Summary
7.4.2 Boehringer Ingelheim Business Overview
7.4.3 Boehringer Ingelheim Anti-obesity Medicine Major Product Offerings
7.4.4 Boehringer Ingelheim Anti-obesity Medicine Revenue in Global Market (2018-2023)
7.4.5 Boehringer Ingelheim Key News & Latest Developments
7.5 Eisai
7.5.1 Eisai Company Summary
7.5.2 Eisai Business Overview
7.5.3 Eisai Anti-obesity Medicine Major Product Offerings
7.5.4 Eisai Anti-obesity Medicine Revenue in Global Market (2018-2023)
7.5.5 Eisai Key News & Latest Developments
7.6 GlaxoSmithKline
7.6.1 GlaxoSmithKline Company Summary
7.6.2 GlaxoSmithKline Business Overview
7.6.3 GlaxoSmithKline Anti-obesity Medicine Major Product Offerings
7.6.4 GlaxoSmithKline Anti-obesity Medicine Revenue in Global Market (2018-2023)
7.6.5 GlaxoSmithKline Key News & Latest Developments
7.7 Orexigen Therapeutics
7.7.1 Orexigen Therapeutics Company Summary
7.7.2 Orexigen Therapeutics Business Overview
7.7.3 Orexigen Therapeutics Anti-obesity Medicine Major Product Offerings
7.7.4 Orexigen Therapeutics Anti-obesity Medicine Revenue in Global Market (2018-2023)
7.7.5 Orexigen Therapeutics Key News & Latest Developments
7.8 Vivus
7.8.1 Vivus Company Summary
7.8.2 Vivus Business Overview
7.8.3 Vivus Anti-obesity Medicine Major Product Offerings
7.8.4 Vivus Anti-obesity Medicine Revenue in Global Market (2018-2023)
7.8.5 Vivus Key News & Latest Developments
7.9 Pfizer
7.9.1 Pfizer Company Summary
7.9.2 Pfizer Business Overview
7.9.3 Pfizer Anti-obesity Medicine Major Product Offerings
7.9.4 Pfizer Anti-obesity Medicine Revenue in Global Market (2018-2023)
7.9.5 Pfizer Key News & Latest Developments
7.10 Roche
7.10.1 Roche Company Summary
7.10.2 Roche Business Overview
7.10.3 Roche Anti-obesity Medicine Major Product Offerings
7.10.4 Roche Anti-obesity Medicine Revenue in Global Market (2018-2023)
7.10.5 Roche Key News & Latest Developments
7.11 Merck
7.11.1 Merck Company Summary
7.11.2 Merck Business Overview
7.11.3 Merck Anti-obesity Medicine Major Product Offerings
7.11.4 Merck Anti-obesity Medicine Revenue in Global Market (2018-2023)
7.11.5 Merck Key News & Latest Developments
7.12 Novo Nordisk
7.12.1 Novo Nordisk Company Summary
7.12.2 Novo Nordisk Business Overview
7.12.3 Novo Nordisk Anti-obesity Medicine Major Product Offerings
7.12.4 Novo Nordisk Anti-obesity Medicine Revenue in Global Market (2018-2023)
7.12.5 Novo Nordisk Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Anti-obesity Medicine Market Opportunities & Trends in Global Market
Table 2. Anti-obesity Medicine Market Drivers in Global Market
Table 3. Anti-obesity Medicine Market Restraints in Global Market
Table 4. Key Players of Anti-obesity Medicine in Global Market
Table 5. Top Anti-obesity Medicine Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Anti-obesity Medicine Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Anti-obesity Medicine Revenue Share by Companies, 2018-2023
Table 8. Global Companies Anti-obesity Medicine Product Type
Table 9. List of Global Tier 1 Anti-obesity Medicine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Anti-obesity Medicine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Anti-obesity Medicine Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Anti-obesity Medicine Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Anti-obesity Medicine Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Anti-obesity Medicine Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Anti-obesity Medicine Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Anti-obesity Medicine Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Anti-obesity Medicine Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Anti-obesity Medicine Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Anti-obesity Medicine Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Anti-obesity Medicine Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Anti-obesity Medicine Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Anti-obesity Medicine Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Anti-obesity Medicine Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Anti-obesity Medicine Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Anti-obesity Medicine Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Anti-obesity Medicine Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Anti-obesity Medicine Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Anti-obesity Medicine Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Anti-obesity Medicine Revenue, (US$, Mn), 2024-2029
Table 30. Alizyme Company Summary
Table 31. Alizyme Anti-obesity Medicine Product Offerings
Table 32. Alizyme Anti-obesity Medicine Revenue (US$, Mn) & (2018-2023)
Table 33. Alizyme Key News & Latest Developments
Table 34. Amylin Pharmaceuticals Company Summary
Table 35. Amylin Pharmaceuticals Anti-obesity Medicine Product Offerings
Table 36. Amylin Pharmaceuticals Anti-obesity Medicine Revenue (US$, Mn) & (2018-2023)
Table 37. Amylin Pharmaceuticals Key News & Latest Developments
Table 38. Arena Pharmaceuticals Company Summary
Table 39. Arena Pharmaceuticals Anti-obesity Medicine Product Offerings
Table 40. Arena Pharmaceuticals Anti-obesity Medicine Revenue (US$, Mn) & (2018-2023)
Table 41. Arena Pharmaceuticals Key News & Latest Developments
Table 42. Boehringer Ingelheim Company Summary
Table 43. Boehringer Ingelheim Anti-obesity Medicine Product Offerings
Table 44. Boehringer Ingelheim Anti-obesity Medicine Revenue (US$, Mn) & (2018-2023)
Table 45. Boehringer Ingelheim Key News & Latest Developments
Table 46. Eisai Company Summary
Table 47. Eisai Anti-obesity Medicine Product Offerings
Table 48. Eisai Anti-obesity Medicine Revenue (US$, Mn) & (2018-2023)
Table 49. Eisai Key News & Latest Developments
Table 50. GlaxoSmithKline Company Summary
Table 51. GlaxoSmithKline Anti-obesity Medicine Product Offerings
Table 52. GlaxoSmithKline Anti-obesity Medicine Revenue (US$, Mn) & (2018-2023)
Table 53. GlaxoSmithKline Key News & Latest Developments
Table 54. Orexigen Therapeutics Company Summary
Table 55. Orexigen Therapeutics Anti-obesity Medicine Product Offerings
Table 56. Orexigen Therapeutics Anti-obesity Medicine Revenue (US$, Mn) & (2018-2023)
Table 57. Orexigen Therapeutics Key News & Latest Developments
Table 58. Vivus Company Summary
Table 59. Vivus Anti-obesity Medicine Product Offerings
Table 60. Vivus Anti-obesity Medicine Revenue (US$, Mn) & (2018-2023)
Table 61. Vivus Key News & Latest Developments
Table 62. Pfizer Company Summary
Table 63. Pfizer Anti-obesity Medicine Product Offerings
Table 64. Pfizer Anti-obesity Medicine Revenue (US$, Mn) & (2018-2023)
Table 65. Pfizer Key News & Latest Developments
Table 66. Roche Company Summary
Table 67. Roche Anti-obesity Medicine Product Offerings
Table 68. Roche Anti-obesity Medicine Revenue (US$, Mn) & (2018-2023)
Table 69. Roche Key News & Latest Developments
Table 70. Merck Company Summary
Table 71. Merck Anti-obesity Medicine Product Offerings
Table 72. Merck Anti-obesity Medicine Revenue (US$, Mn) & (2018-2023)
Table 73. Merck Key News & Latest Developments
Table 74. Novo Nordisk Company Summary
Table 75. Novo Nordisk Anti-obesity Medicine Product Offerings
Table 76. Novo Nordisk Anti-obesity Medicine Revenue (US$, Mn) & (2018-2023)
Table 77. Novo Nordisk Key News & Latest Developments
List of Figures
Figure 1. Anti-obesity Medicine Segment by Type in 2022
Figure 2. Anti-obesity Medicine Segment by Application in 2022
Figure 3. Global Anti-obesity Medicine Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Anti-obesity Medicine Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Anti-obesity Medicine Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Anti-obesity Medicine Revenue in 2022
Figure 8. By Type - Global Anti-obesity Medicine Revenue Market Share, 2018-2029
Figure 9. By Application - Global Anti-obesity Medicine Revenue Market Share, 2018-2029
Figure 10. By Type - Global Anti-obesity Medicine Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Anti-obesity Medicine Revenue Market Share, 2018-2029
Figure 12. By Application - Global Anti-obesity Medicine Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Anti-obesity Medicine Revenue Market Share, 2018-2029
Figure 14. By Region - Global Anti-obesity Medicine Revenue Market Share, 2018-2029
Figure 15. By Country - North America Anti-obesity Medicine Revenue Market Share, 2018-2029
Figure 16. US Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Anti-obesity Medicine Revenue Market Share, 2018-2029
Figure 20. Germany Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 21. France Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Anti-obesity Medicine Revenue Market Share, 2018-2029
Figure 28. China Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 32. India Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Anti-obesity Medicine Revenue Market Share, 2018-2029
Figure 34. Brazil Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Anti-obesity Medicine Revenue Market Share, 2018-2029
Figure 37. Turkey Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Anti-obesity Medicine Revenue, (US$, Mn), 2018-2029
Figure 41. Alizyme Anti-obesity Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Amylin Pharmaceuticals Anti-obesity Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Arena Pharmaceuticals Anti-obesity Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Boehringer Ingelheim Anti-obesity Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Eisai Anti-obesity Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. GlaxoSmithKline Anti-obesity Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Orexigen Therapeutics Anti-obesity Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Vivus Anti-obesity Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Pfizer Anti-obesity Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Roche Anti-obesity Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Merck Anti-obesity Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Novo Nordisk Anti-obesity Medicine Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 抗肥満薬の世界市場見通し2023年-2029年(Anti-obesity Medicine Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • ペット肥満管理の世界市場見通し2023年-2029年
  • 抗肥満薬の世界市場2022：内服薬、ダイエットパッチ、その他
  • 老化防止剤の世界市場見通し2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆